1	Title: Low seroprevalence of Ebola virus in health care providers in an endemic region
2	(Tshuapa province) of the Democratic Republic of the Congo
3	Trésor Zola Matuvanga <sup>1,2,3*</sup> , Joachim Mariën <sup>4</sup> , Ynke Larivière <sup>2,3</sup> , Bernard Osangir <sup>2,3</sup> , Solange
4	Milolo <sup>1</sup> , Rachel Meta <sup>1</sup> , Emmanuel Esanga <sup>5</sup> , Vivi Maketa <sup>1</sup> , Junior Matangila <sup>1</sup> , Patrick Mitashi <sup>1</sup> ,
5	Steve Ahuka Mundeke <sup>6</sup> , Hypolite Muhindo-Mavoko <sup>1</sup> , Jean-Jacques Muyembe Tamfum <sup>6</sup> , Pierre
6	Van Damme <sup>2</sup> , Jean-Pierre Van geertruyden <sup>3</sup>
7	Affiliations
8	<sup>1</sup> Tropical Medicine Department, University of Kinshasa, Kinshasa, Democratic Republic of the
9	Congo
10	<sup>2</sup> Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of
11	Antwerp, Wilrijk, Belgium
12	<sup>3</sup> Global Health Institute, Department of Family Medicine and Population Health, University of
13	Antwerp, Wilrijk, Belgium.
14	<sup>4</sup> Department of Biology, Evolutionairy Ecology group, University of Antwerp, Wilrijk, Belgium
15	<sup>5</sup> Division Provinciale de la Santé de la Tshuapa, Democratic Republic of the Congo
16	<sup>6</sup> Institut National de Recherches Biomedicales, Department of Virology (INRB) and University of
17	Kinshasa, Service of Microbiology
18	*Corresponding author: Department of Tropical Medicine, University of Kinshasa, Avenue
19	Université numéro 1, Commune de Lemba, Kinshasa, Democratic Repuplic of the Congo,
20	Phone: +243 81004630,
21	Email: zolanga@yahoo.fr
22	
23	

Page 2 sur 26

# 24 Abstract

25

26 Introduction: A serosurvey among health care providers (HCPs) and frontliners of an

- 27 area previously affected by Ebola virus disease (EVD) in the Democratic Republic of the
- 28 Congo (DRC) was conducted to assess the seroreactivity to Ebola virus antigens.
- 29 Methods: Serum samples were collected in a cohort of HCPs and frontliners (n=698)
- 30 participants in the EBL2007 vaccine trial (December 2019 to October 2022). Specimens
- 31 seroreactive for EBOV were confirmed using either the Filovirus Animal Nonclinical Group
- 32 (FANG) ELISA or a Luminex multiplex assay.

33 **Results**: The seroreactivity to at least two EBOV-Mayinga (m) antigens was found in 10

34 (1.4%: 95% CI, 0.7- 2.6) samples for GP-EBOV-m + VP40-EBOV-m, and 2 (0.3%: 95%

35 CI, 0.0 - 1.0) samples for VP40-EBOV-m + NP-EBOV-m using the Luminex assay.

36 Seroreactivity to GP-EBOV-Kikwit (k) was observed in 59 (8.5%: 95%CI, 6.5-10.9)

37 samples using FANG ELISA.

Conclusion: In contrast to previous serosurveys, a low seroprevalence was found in the HCP and frontline population participating in the EBL2007 Ebola vaccine trial in Boende, DRC. This underscores the high need for standardized antibody assays and cutoffs in EBOV serosurveys to avoid the broad range of reported EBOV seroprevalence rates in EBOV endemic areas.

43 Key words: EBOV, DRC, EBL2007 trial, GP-EBOV, Luminex, FANG ELISA, Boende,
44 Health care providers, Frontliners.

45

46 **Abstract words count**:195

Page 3 sur 26

# 48 Introduction

49

Ebola virus disease (EVD) was first observed during two simultaneous epidemics in 1976 50 51 in South Sudan and the Democratic Republic of the Congo (DRC) [1, 2]. Since then, there 52 were fifteen epidemics throughout the DRC, including one in the Boende area, province 53 of Tshuapa in 2014 [3, 4]. The frequency of EVD epidemics in the DRC increased 54 tremendously over the past five years with seven epidemics occurring between 2017 and 55 2022. Mathematical models predict at least one epidemic each year [5]. The increasing 56 trend can partly be explained by an improved surveillance system and better diagnostic 57 tools. Further, villagers are more likley to come into contact with the natural reservoir of 58 Ebolavirus Zaire (EBOV), as pristine habitats in the Congo Basin are transformed into 59 farmland and cut at an unprecedented rate to provide wood for industries [6]. Human 60 encroachment into these new habitats results in increased bushmeat hunting and a higher 61 level of exposure to the virus, which is most likely spilled over from bats or monkeys [7]. 62 Furthermore, flare-ups of EVD epidemics might also result from chronically infected 63 patients, which was noted recently in Guinea where a survivor passed the virus on to his partner via semen more than 500 days after contracting EVD [5, 8, 9]. 64

65 While spillover from animals to humans is considered to be rare [10], epidemics are 66 primarily the result of direct person-to-person transmission via body fluids or indirect 67 transmission via contaminated materials [11]. Due to occupational exposure, healthcare 68 providers (HCPs) are more at risk during an outbreak than others in the general 69 community and become a potential source of transmission themselves [12]. For example, 70 during the seventh EVD outbreak in the DRC, which occurred in Boende Health District 71 (2014), three HCPs were identified as potential super-spreaders of community-level 72 disease transmission [13]. Similarly, health facilities may facilitate transmission to the

Page **4** sur **26** 

community as infected patients, visitors, and the general public come together there [14,
15]. For example, the EBOV epidemic in 1995 was mainly driven by nosocomial
transmission at Kikwit General Hospital of DRC [16].

76 While epidemics are typically monitored through PCR-confirmed active cases, 77 serosurveillance data represents the accumulative number of infections and may detect several undiagnosed cases. Indeed, EBOV infections may remain asymptomatic or 78 79 paucisymptomatic after exposure to the pathogen [17]. This has been observed in recent 80 studies where EBOV antigen seroreactivity is increasingly reported [8, 18, 19]. In 81 unaffected areas, seroreactivity to EBOV-GP was reported in urban areas of Cameroon 82 (1.3%), and DRC in Kinshasa (2%) and Kasaï Oriental (3.5%) [8, 18, 20, 21]. In a resident 83 pygmy population including traditional hunters in Watsa locality (Haut-Uele province, 84 DRC) a seroprevalence of 18.7% was reported [8]. A study including HCP and frontliners, 85 regardless of their self-reported history of EVD, found 3.4% of EBOV antigens seroreactivity in Kabondo - Dianda (southeastern DRC and forest-savannah area) [22]. A 86 87 serosurvey conducted at the end of the 2014-2016 epidemic in Sierra Leone showed a 88 seroreactivity of 8% among apparently healthy participants volunteering for an Ebola 89 vaccine trial, with no self-reported history of EVD [23]. Serosurveys in the DRC obtained 90 highly variable seroprevalence estimates depending on the region and the target group. 91 While the EBOV seroprevalence in Boende after the previous epidemic of 2014 was high 92 (28.1%) among healthy HCP never reporting an infection [24], the seroprevalence 93 estimate was much lower in another study conducted in the same area (7%) [22]. A 94 serosurvey conducted on blood samples collected from clinically suspected EVD cases 95 that were sent home after testing negative in two consecutive EBOV RT-PCR during the

Page 5 sur 26

tenth EBOV outbreak in DRC Ituri, Nord Kivu and Sud Kivu provinces, 2018-2020),
reported an EBOV antigen seroreactivity of 2.3% [25] (Table 1).

98 However, despite many studies assessing the GP-EBOV antigen seroreactivity in different 99 populations and different locations/countries, the interpretation of this seroprevalence 100 data is challenging given the variation of the assays employed and diversity of cutoff 101 algorithms used [8, 12, 18, 26-28]. Seroreactivity to a single EBOV antigen may not be 102 sufficient to demonstrate prior exposure to EBOV, especially in asymptomatically infected 103 persons [29, 30]. Despite the broad range of EBOV seroprevalence rates in the EBOV 104 endemic areas, previous serological surveys may have overestimated seroprevalence 105 rates due to cross-reactivity against other infectious diseases (i.e. low specificity) [10, 28]. 106 The use of more specific assays to determine the seroreactivity based on at least two 107 antigens may therefore provide a better understanding of the baseline seroprevalence 108 before a vaccine immunogenicity assessment [31, 32].

109 The study presented here, combines (1) the seroresults of baseline blood samples 110 collected among HCP and frontliners participating in the EBL2007 vaccine trial which 111 evaluates the safety and immunogenicity of the two-dose Ad26.ZEBOV, MVA-BN-Filo 112 Ebola virus vaccine regimen (ClinicalTrials.gov identifier: NCT04186000) with (2) the 113 results from an ecological survey to determine information related to the current and past 114 residence and work locations of a cohort of HCP included in the EBL2007 vaccine trial 115 [33]. On the baseline blood samples collected, pre-existing antibodies against EBOV 116 among the participants were assessed using both FANG ELISA and Luminex assay. 117 While the first assay only targets IgG antibodies against the glycoprotein (GP) of EBOV, 118 the second assay also tartgets the nucleocapsid (NP) and the viral matrix protein 40 119 (VP40) which increases its specificity to 99% [34]. This manuscript reports the baseline

Page 6 sur 26

- 120 seroprevalence of Ebolavirus Zaire (EBOV) among HCP and frontliners participants in the
- 121 EBL2007 trial conducted in the health district of Boende in DRC.

Page 7 sur 26

#### 122 **Materials and Methods**

123

#### 124 **Origin of samples**

125

126 Baseline serum samples were collected before vaccination in an open-label, monocentric, phase 2, randomized trial to evaluate the immunogenicity and safety of Ad26.ZEBOV and 127 128 MVA-BN-Filo in healthy HCP and frontliners in Boende Health District of DRC (EBL2007 129 trial, ClinicalTrials.Gov: NCT04186000) [33]. The trial site was located in the Boende 130 General Hospital of Tshuapa province at approximately 750 km north-west of the capital 131 city of Kinshasa in DRC. Blood samples were collected from healthy participants with no 132 reported history of EVD or previous EBOV vaccination. During the first visit of the 133 EBL2007 trial serum samples were collected for baseline determination of IgG GP-EBOV 134 by the means of FANG ELISA and Luminex assay. At one year after inclusion of participants in the EBL2007 vaccine trial, a survey nested within the EBL2007 vaccine 135 trial collected information related to where HCPs and frontliners lived and worked in the 136 137 past, and their previous contacts with EVD cases.

### 138

139

# **Operational definition**

The HCP term in the EBL2007 vaccine trial included medical doctors, nurses, midwives. 140 141 laboratory staff, pharmacy staff, hygienists, health facility cleaners, and nursing assistants 142 working in a hospital, Health Center, Health Post, or Health District office. Frontliners 143 encompassed community health workers, first aiders, and those working in the Health 144 District office and or the Provincial Division of Health. Direct contact was defined as any 145 HCP and frontliners who may have had direct interaction with patients infected with EVD 146 at a hospital or treatment center during an outbreak. Indirect contact was considered the

Page 8 sur 26

147	work of frontliners and other HCPs whose jobs did not bring them into direct interaction
148	with sick patients but could bring them in contact with contaminated material.
149	Serological testing
150 151	The study was performed according to the good clinical laboratory practice guidelines of
152	the Division of Acquired Immunodeficiency Syndrome and WHO [35, 36] to ensure high
153	quality, reliable, and reproducible data at Q Squared Solutions (San Juan Capistrano, CA,
154	US) Vaccine Testing Laboratory for FANG ELISA and Institut National de Recherche
155	Biomédicale (INRB) in DRC for the Luminex Assay.

# 156 LUMINEX Assay technology

The serology testing was performed with Luminex Magpix<sup>®</sup> technology (Luminex Corp., 158 159 Austin, TX) as per the previously published protocol [17, 32]. Four recombinant 160 commercially available EBOV antigens were coated onto magnetic beads: two 161 glycoproteins, GP-EBOV-kis (Kissidougou/Makona 2014 strain) and GP-EBOV-m 162 (Mayinga 1976 strain); 1 nucleoprotein, NP-EBOV-m (Mayinga 1976 strain); and 1 40-163 kDa viral protein (VP40-EBOV-m, Mayinga 1976 strain). The bead-coupled antigens were 164 mixed with the patient sample (1:1000 sample to dilution buffer), and the signal from the 165 response for anti-EBOV immunoglobulin G (anti-IgG) was read and stored on Bio-Plex 166 200 hardware (Bio-Rad, Marnes-la-Coquette, France). All results were reported as the 167 median fluorescence intensity (MFI). Based on the serological responses, a participant 168 was deemed to bear the pre-existing antibodies against EBOV antigens when the sample 169 was reactive above the cutoff for at least two different EBOV antigens.

170

157

Page 9 sur 26

## 172 FANG ELISA

173 The methods used to perform the FANG ELISA have been described in previous studies 174 [37]. Before the addition of test samples, 96-well microplates were coated with 100 µL of 175 recombinant GP-EBOV-Kikwit (k) and incubated at 4°C in the absence of light. In addition 176 to this, a standard obtained from one or more serially diluted vaccinated donors had been 177 added. Incubation was performed by adding horseradish peroxidase conjugate from goat 178 anti-human IgG to each well. The substrate 3, 3', 5, 5'-tetramethylbenzidine was then 179 incorporated into each well. The addition of sulfuric acid solution stopped the enzymatic 180 reaction. The color change was then observed with a plate reader. The plate reader was 181 used to report the quality controls as well as the concentrations of the added samples. 182 The concentrations of these samples were based on the standard curve calculated using 183 a 4-parameter logistic curve (4PL) and are expressed as ELISA units/ml (EU/ml). Final 184 titers were determined based on a cutoff optical density (OD) value and were reported as 185 the reciprocal of the highest dilution with a positive OD value.

186

188

# 187 Sample Size and Statistical Analysis

The number of participants eligible for the EBL2007 trial with available aliquots (n=698) at the inclusion visit predetermined the number of enrolled subjects in the serosurvey. Subjects reacting to EBOV antigens (GP, NP, VP40) were summarized using proportions with 95% confidence interval. Demographic and ecological data were compiled and summarized using descriptive statistics for all participants enrolled in the EBL2007 vaccine trial using SPSS 28.0 IBM SPSS Statistics for Windows, version 28.0 and R 4.2.1 Statistical Software.

Page 10 sur 26

Both the FANG ELISA and Luminex assay do not have an established cutoff to distinguish individuals with seroreactivity to an EBOV antigen. In the absence of a representive control panel to estimate a cutoff, we calculated cutoff values by change point analysis [38] using R [39]. In the supplementary information, we also provide seroprevalence estimates based on cutoff values obtained from literature.

201 To further investigate if the signal of the antibody assay represents true past exposure to 202 EBOV, we tested if participants from the EBOV risk groups (based on age, sex, direct or 203 indirect contact with patients in general, working in a hospital or elsewhere, previous 204 contact with Ebola patients or experienced an outbreak at a location where you lived) were 205 significantly more likely to be antibody positive. We used a generalized linear model with 206 binomial link function. For each individual antigen, the participant's seropositivity status 207 was included as response variable and the participant characteristics as explanatory 208 variables. Only combinations of the Luminex GP-EBOV-m+VP40-EBOV were considered, 209 as the sample size of the positive group was too small for all other combinations. P-values were considered significant below a value of 0.05. 210

Page 11 sur 26

## 211 Ethics statements

The National Ethics Committee of the DRC Ministry of Health approved the study protocol of EBL2007 (approval reference n°121/CNES/BN/PMMF/2019). The ecological survey nested in the EBL2007 Vaccine trial was approved by the National Ethics Committee of the DRC Ministry Health under approval reference n°212/CNES/BN/PMMF/2020. For both the EBL2007 trial and the ecological survey participants provided written informed consent.

- 218
- 219 Results

#### 220 Participants characteristics

A total of 720 HCPs and frontliners were screened for inclusion in the EBL2007 trial. of 221 222 which 699 (96.9%) agreed to participate in the baseline seroprevalence study. However, 223 one participant withdrew consent prior to blood collection. Thus, blood samples were 224 available for 698 (99.9%) participants with a mean age of 45 years (standard 225 deviation=12.0) and 534 (76.5%) were male (Table 2). Nearly two-thirds of the HCPs and 226 frontliners [492 (70.5%)] worked in a health facility in the Boende Health District and 410 227 (59.0%) were HCPs working in direct contact with patients. Forty-three (6.2%) of them 228 reported a direct contact with patients during a previous Ebola outbreak in Boende or 229 elsewhere. From a minority (3.5%) we are not sure if they ever had contact with infectious patients during an ebola outbreak. 230

Page 12 sur 26

231	
232 233	Seroreativity to EBOV proteins using FANG ELISA and or Luminex
234	When considering antibody responses against EBOV antigens individually, we found that
235	8.4% (59/698; 95%CI 6.5 -10.6) of samples tested positive on the Luminex for GP-EBOV-
236	m, 9.4% (66/698;95%CI 7.5 -11.8) for GP- EBOV-kis, 9.4% (87/698;95%CI10.3-12.9) for
237	VP40-EBOV-m, and 1.3% (9/698;95%CI0.6-2.6) for NP-EBOV-m (Table 3). The
238	seroreactivity to at least two EBOV antigens using Luminex was encountered in 1.4%
239	(10/698;95%CI0.7-2.6) and 0.3% (2/698;95%CI0.0-1.0) of sera for VP40-EBOV-m + GP-
240	EBOV-m and VP40-EBOV-m + NP-EBOV-m respectively. No sera tested positive for NP-
241	EBOV-m+GP-EBOV-m.
242	GP-EBOV-m seroreactivity on the FANG ELISA was found in 7.1% (49/698; 95%CI6.5-
243	10.9) of participants' sera. Looking at participants whose GP-EBOV seroreactivity was
244	identified in both Luminex and FANG ELISA, 0.8% (6/694; 95%CI0.1-1.5) of the tested
245	samples were positive. We performed seroreactivity analyses using cutoffs determined in
246	the literature and found similar results as depicted in the Supplementary material.
247	A weak correlation between the FANG ELISA and Luminex was shown (k=0.2) (Figure 1).
248	In seeking which participant characteristics influenced seropositivity, we observed
249	significant differences in the seropositivity rate between HCPs and frontliners who
250	previously made direct contact with an Ebola patient or experienced an outbreak in their
251	hometown. When looking at the GP-EBOV-k antigen, HCPs and frontliners who previously
252	became into contact with Ebola were significantly less likely to be seropositive compared
253	to HCPs and frontliners who never experienced an Ebola outbreak (estimate=-1.22, std.
254	error = 0.52, P=0.02). When looking at the GP-EBOV-m, seropositivity status significantly
255	decreased with age (estimate = $-0.02$ , est.error = $0.01$ , P= $0.04$ ).

Page 13 sur 26

# 256 **Discussion**

257

258 We report the baseline seroreactivity to EBOV-m antigens in apparently healthy HCPs 259 and frontliners enrolled in the EBL2007 vaccine trial.

260 Based on seroreactivity in two different assay formats (FANG ELISA and Luminex), only

a minority (0.8%) of HCPs and frontliners blood samples seroreacted to the GP-EBOV-m

surface antigen. Similarly, a minority of participants sera tested positive to at least two

antigens on the Luminex (0.3% for NP+VP40 EBOV-m and 1.4 for GP-EBOV-m+VP40-

EBOV-m). None of the participants sera tested positive to GP-EBOV-m+NP-EBOV-m.

Additionally, when we investigated whether seropositivity correlated with participants' prior exposure to EBOV-m, we did not observe a relevant positive correlation. This suggests that the majority of seropositive participants implied on the basis of the single antigen analysis are in fact false positives.

269 Overall, these results suggest that the baseline seroprevalence against EBOV-m in HCPs 270 and frontliners in Boende is very low. Our seroprevalence estimates are much lower 271 compared to previous serosurveys conducted after the EVD outbreak of 2014 in HCP of 272 Boende Health District (22.5% and 28%) (GP-EBOV-m seroreactivity using ELISA) [12, 273 27]. Our estimates are also lower than the one previously reported in Boende Health 274 District among the general population (7%) (GP-EBOV-m seroreactivity using ELISA) a 275 year after the 2014 Ebola epidemic [22]. The seroprevalence based on one EBOV-m 276 antigen (GP-EBOV-m) found in this study using either ELISA or Luminex is lower than 277 other peviously reported in the Watsa Pygmy population of DRC in 2002 (18.7%) (GP-278 EBOV-m seroreactivity using ELISA) and the Sankuru rural population in 2007 (11%) (GP-279 EBOV-m seroreactivity using ELISA) [8, 21].

Page 14 sur 26

By employing this approach, our seroprevalence estimates became comparable to those
of previous serological surveys conducted in Kikwit (2.2%) (GP-EBOV-m seroreactivity by
ELISA) and Kinshasa (2%) (GP-EBOV-m seroreactivity by luciferase immunoprecipitation
system + neutralization) [18, 40].
It is worth noting that LUMINEX built on an approach of simultaneously targeting multiple

EBOV antigens, demonstrated a specificity (99.1%) and a sensitivity (95.7%) similar to higher than, respectively, the specificity (100%) and sensitivity (92.5%) of the commercial ELISA in a study [32]. The FANG ELISA was developed and validated to quantify Filovirus anti-EBOV-GP immunoglobulin G (IgG) binding antibodies in human and non-human primate serum sample to enable bridging of immunogenicity data between humans and animal models in vaccine trials [37].

291 The higher seroprevalences found in other serosurveys conducted in Boende or 292 elsewhere in the DRC may be explained by the fact that different assays were used in the 293 different studies, other cutoff algorithms were used, and the definition of reactivity discrimination (one or two EBOV antigens) may have decreased the specificity of these 294 295 assays. This could have led to overestimation of EBOV antigen seropositivity. On the other 296 hand, it cannot be ruled out that more people were indeed infected during the 2014 297 outbreak in Boende and that antibody titers waned over time or at least dropped below 298 the detection threshold, explaining the low seroprevalence that we observed. Likewise, this low prevalence may reflect a rare incidence of asymptomatic EBOV infection among 299 300 HCP and frontliner population from the Boende Health District. The previous scenario may 301 reflect a susceptibility to future outbreaks of EBOV. Yet, negative antibody titers doe not 302 rule out other types of immunity, such asT-cell immunity [41].

Page 15 sur 26

303 FANG ELISA or Luminex are assays that can only detect binding antibodies and are 304 unable to differentiate them from neutralizing antibodies [37]. The latter are typically 305 detected using neutralization assays, which are still considered the gold standard for 306 serological testing [42, 43]. However, such testing involves infectious cells, are labour 307 intenstive and time consuming [44]. For viruses such as EBOV, all experiments should be 308 performed under a biosafety laboratory (BSL)-4 conditions, which are limited in availability 309 and expensive to operate [45]. Thus, it is beneficial to use alternative neutralization assays 310 that do not require viruses or live cells, and that can be performed in BSL-2 laboratories 311 to assess neutralizing antibody capacity [44, 46]. These alternative assays should 312 conclude if a person with high binding antibodies against EBOV (based on FANG ELISA 313 or Luminex) was indeed infected with the virus (although some level of cross-reactivity 314 can never be ruled out) [29]. The challenge of comparing different serosurveys that have 315 assessed the EBOV seroprevalence makes the implementation of international 316 standardization of units for EBOV antibody detection and quantification of paramount 317 importance [47].

The poor linear relationship between the two assays used (FANG ELISA and Luminex) in this serosurvey confirms that both assays likely contain many false positive results, when using single antigens. Hence, the reported seropositivity could be an effect of other filoviruses or infectious microbes, which may cause cross-reactions [48].

A limitation of our study is the lack of positive and negative control samples to determine the positive cutoff. However, in the absence of a standard serological assay for EBOV seroreactivity, Luminex can still be employed in serosurveys due to its ability to detect seroreactivity to combinations of different EBOV antigens [32].

Page 16 sur 26

326 The strength of this survey resides in the use of high cutoffs to determine the EBOV 327 seropositivity that aligns with recommendations in EBOV serosurveys generally applied 328 to Congolese cohorts [18, 28, 49]. Thus, the combination of FANG ELISA and Luminex 329 results can be considered a starting point, showing how previous serological surveys may 330 have overestimated the seroprevalence of EBOV in a non-exempt area. Like the recent 331 index case of the fourteenth outbreak in DRC (Mbandaka, 2022), whose symptoms began 332 three weeks after returning from Boende with no notion of contact with an Ebola survivor 333 [5]. The next step could be the use of a neutralization assay for assessment of neutralizing 334 antibodies among this population of HCP and frontliners participants in the EBL2007 trial 335 to further document whether or not this population of HCP is naive to EBOV exposure. 336 The low baseline seroreactivity to EBOV antigens observed in HCP and frontliner

population of Boende suggests that the majority of this population never came into contact with the virus, despite the fact the many HCP and frontliners worked during previous EBV outbreak in 2014. In the event of a future epidemic, mathematical models suggested that the vaccination rate of HCP in an infected area should be at least (30%) to prevent a major epidemic [50]. Therefore it is clear that HCP in endemic regions should be primary targets for vaccination in the frame of the Ebola epidemic preparedness plan in DRC [50].

Page 17 sur 26

# 343 Conclusion

344

In contrast to previous studies that observed high seroreactivity against EBOV-m in 345 346 Boende, our results show that the baseline seroprevalence of HCP and frontliners that reported no previous EBOV infections is low. This suggests that asymptomatic infections 347 348 are unlikely to occur or that antibodies rapidly wane after infection (or at least drop below 349 the cutoff of detection). Irrespective of the cause, it means that the majority of HCPs in 350 the area are likely susceptible to EVD despite the history of outbreaks in and the area of 351 Boende. Given the high variance between seroprevalence estimates by different studies 352 in the same region, we highlight the need for more uniform antibody assays. Neutralizing antibody quantification methods, which are inexpensive in terms of resources, are likely 353 to be crucial for improving EVD surveillance in this region, given the high background of 354 355 concomitant parasitic disease burden that can be expected to be found in the serum of 356 this population. Low resources affordable approaches to quantifying neutralizing 357 antibodies are likely to be crucial in enhancing surveillance of EVD disease in this region.

#### 358 Acknowledgments

359

The authors gratefully acknowledge the hard work and dedication of the local trial staff. The supportive role of ACE Research, DFNet Research, Q<sup>2</sup> Solutions and Institut National de Rechrche Biomédicale (INRB) and all partners within the EBOVAC3 Consortium is highly appreciated.

Page 18 sur 26

## **Financial support**

365

This work was supported by the EBOVAC3. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 800176 (IMI-EU). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation pro-gramme, European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Coalition for Epidemic Preparedness Innovations (CEPI). All vaccines were provided by Janssen Vaccines & Prevention B.V.

# **Potential conflicts of interest**

373

374 The authors declare that they have no known competing financial interests or personal

375 relationships that could have appeared to influence the work reported in this paper.

Page 19 sur 26

#### 377 References 378 379 1. Team WIS: Ebola haemorrhagic fever in Sudan, 1976. Bulletin of the World Health Organization 380 1978, 56(2):247-270. 381 2. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978, 56(2):271-293. 382 Epidémie de la Maladie à Virus Ebola, Province de l'Equateur, République Démocratique du 3. 383 Congo (24/04/2022) [https://reliefweb.int/organization/who] 384 Le Gouvernement déclare la fin de l'épidémie de la maladie à virus Ebola dans la Zone de santé 4. 385 de Boende | Province de l'Equateur, Nord-ouest de la RDC 386 [https://reliefweb.int/organization/who] 387 5. Makoni M: Ebola outbreak in DR Congo. The Lancet 2022, 399(10337):1766. 388 6. Tyukavina A, Hansen MC, Potapov P, Parker D, Okpa C, Stehman SV, Kommareddy I, Turubanova 389 S: Congo Basin forest loss dominated by increasing smallholder clearing. Science advances 390 2018, 4(11):eaat2993. 391 7. Gryseels S, Mbala-Kingebeni P, Akonda I, Angoyo R, Ayouba A, Baelo P, Mukadi DB, Bugentho E, 392 Bushmaker T, Butel C et al: Role of Wildlife in Emergence of Ebola Virus in Kaigbono (Likati), 393 Democratic Republic of the Congo, 2017. Emerg Infect Dis 2020, 26(9):2205-2209. 394 Mulangu S, Borchert M, Paweska J, Tshomba A, Afounde A, Kulidri A, Swanepoel R, Muyembe-8. 395 Tamfum J-J, Van der Stuyft P: High prevalence of IgG antibodies to Ebola virus in the Efé pygmy 396 population in the Watsa region, Democratic Republic of the Congo. BMC infectious diseases 397 2016, **16**(1):1-6. 398 Diallo B, Sissoko D, Loman NJ, Bah HA, Bah H, Worrell MC, Conde LS, Sacko R, Mesfin S, Loua A: 9. 399 Resurgence of Ebola virus disease in Guinea linked to a survivor with virus persistence in 400 seminal fluid for more than 500 days. Clinical infectious diseases 2016, 63(10):1353-1356. 401 10. de La Vega M-A, Stein D, Kobinger GP: Ebolavirus evolution: past and present. PLoS pathogens 402 2015, **11**(11):e1005221. 403 11. Dhama K, Malik YS, Malik SVS, Singh RK: Ebola from emergence to epidemic: the virus and the 404 disease, global preparedness and perspectives. The Journal of Infection in Developing Countries 405 2015, 9(05):441-455. 406 Doshi RH, Hoff NA, Bratcher A, Mukadi P, Gadoth A, Nicholson BP, Williams R, Mukadi D, 12. 407 Mossoko M, Wasiswa J: Risk Factors for Ebola Exposure in Health Care Workers in Boende, 408 Tshuapa Province, Democratic Republic of the Congo. The Journal of Infectious Diseases 2020. 409 13. Maganga GD, Kapetshi J, Berthet N, Kebela Ilunga B, Kabange F, Mbala Kingebeni P, Mondonge 410 V, Muyembe J-JT, Bertherat E, Briand S: Ebola virus disease in the Democratic Republic of 411 Congo. New England Journal of Medicine 2014, 371(22):2083-2091. 412 14. History of Ebola Virus Disease (EVD) Outbreaks 413 [https://www.cdc.gov/vhf/ebola/history/chronology.html] 414 15. Baller A, Padoveze MC, Mirindi P, Hazim CE, Lotemo J, Pfaffmann J, Ndiaye A, Carter S, Chabrat 415 M-AD, Mangala S: Ebola virus disease nosocomial infections in the Democratic Republic of the 416 Congo: a descriptive study of cases during the 2018–2020 outbreak. International Journal of 417 Infectious Diseases 2022, **115**:126-133. 418 16. Muyembe-Tamfum J, Kipasa M, Kiyungu C, Colebunders R: Ebola outbreak in Kikwit, Democratic 419 **Republic of the Congo: discovery and control measures.** The Journal of infectious diseases 1999, 420 179(Supplement 1):S259-S262. 421 17. Diallo MSK, Rabilloud M, Ayouba A, Touré A, Thaurignac G, Keita AK, Butel C, Kpamou C, Barry

422 TA, Sall MD: Prevalence of infection among asymptomatic and paucisymptomatic contact

Page 20 sur 26

423		persons exposed to Ebola virus in Guinea: a retrospective, cross-sectional observational study.
424		The Lancet Infectious Diseases 2019, <b>19</b> (3):308-316.
425	18.	Steffen I, Lu K, Yamamoto LK, Hoff NA, Mulembakani P, Wemakoy EO, Muyembe-Tamfum JJ,
426		Ndembi N, Brennan CA, Hackett J, Jr. et al: Serologic Prevalence of Ebola Virus in Equatorial
427		Africa. Emerg Infect Dis 2019, 25(5):911-918.
428	19.	Shaffer KC, Hui S, Bratcher A, King LB, Mutombe R, Kavira N, Kompany JP, Tambu M, Musene K,
429		Mukadi P: Pan-ebolavirus serology study of healthcare workers in the Mbandaka Health
430		Region, Democratic Republic of the Congo. PLOS Neglected Tropical Diseases 2022,
431		<b>16</b> (3):e0010167.
432	20.	Moyen N, Thirion L, Emmerich P, Dzia-Lepfoundzou A, Richet H, Boehmann Y, Dimi Y, Gallian P,
433		Gould EA, Günther S: Risk factors associated with Ebola and Marburg viruses seroprevalence in
434		blood donors in the Republic of Congo. PLoS neglected tropical diseases 2015, 9(6):e0003833.
435	21.	Mulangu S, Alfonso VH, Hoff NA, Doshi RH, Mulembakani P, Kisalu NK, Okitolonda-Wemakoy E,
436		Kebela BI, Marcus H, Shiloach J: Serologic evidence of ebolavirus infection in a population with
437		no history of outbreaks in the Democratic Republic of the Congo. The Journal of Infectious
438		Diseases 2018, <b>217</b> (4):529-537.
439	22.	Bratcher A, Hoff NA, Doshi RH, Gadoth A, Halbrook M, Mukadi P, Musene K, Ilunga-Kebela B,
440		Spencer D, Bramble MS et al: Zoonotic risk factors associated with seroprevalence of Ebola
441		virus GP antibodies in the absence of diagnosed Ebola virus disease in the Democratic Republic
442		of Congo. PLoS Negl Trop Dis 2021, 15(8):e0009566.
443	23.	Manno D, Ayieko P, Ishola D, Afolabi MO, Rogers B, Baiden F, Serry-Bangura A, Bah OM, Köhn B,
444		Swaray I et al: Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected
445		by Ebola, Sierra Leone. Emerg Infect Dis 2022, 28(3):734-738.
446	24.	Hoff NA, Mukadi P, Doshi RH, Bramble MS, Lu K, Gadoth A, Sinai C, Spencer D, Nicholson BP,
447		Williams R et al: Serologic Markers for Ebolavirus Among Healthcare Workers in the
448		Democratic Republic of the Congo. J Infect Dis 2019, 219(4):517-525.
449	25.	Nkuba-Ndaye A, Mukadi-Bamuleka D, Bulabula-Penge J, Thaurignac G, Edidi-Atani F, Mambu-
450		Mbika F, Danga-Yema B, Matondo-Kuamfumu M, Kinganda-Lusamaki E, Bisento N: Added value
451		of an anti-Ebola serology for the management of clinically suspected Ebola virus disease
452		patients discharged as negative in an epidemic context. The Journal of Infectious Diseases 2022.
453	26.	Mbala P, Baguelin M, Ngay I, Rosello A, Mulembakani P, Demiris N, Edmunds WJ, Muyembe J-J:
454		Evaluating the frequency of asymptomatic Ebola virus infection. Philosophical Transactions of
455		the Royal Society B: Biological Sciences 2017, <b>372</b> (1721):20160303.
456	27.	Hoff NA, Mukadi P, Doshi RH, Bramble MS, Lu K, Gadoth A, Sinai C, Spencer DA, Nicholson BP,
457		Williams R: Serologic markers for ebolavirus among healthcare workers in the Democratic
458		<b>Republic of the Congo</b> . <i>The Journal of infectious diseases</i> 2019, <b>219</b> (4):517-525.
459	28.	Bratcher A, Hoff NA, Doshi RH, Gadoth A, Halbrook M, Mukadi P, Musene K, Ilunga-Kebela B,
460		Spencer DA, Bramble MS: Zoonotic risk factors associated with seroprevalence of Ebola virus
461		GP antibodies in the absence of diagnosed Ebola virus disease in the Democratic Republic of
462		Congo. PLoS Neglected Tropical Diseases 2021, <b>15</b> (8):e0009566.
463	29.	Richardson ET, Kelly JD, Barrie MB, Mesman AW, Karku S, Quiwa K, Marsh RH, Koedoyoma S,
464		Daboh F, Barron KP: Minimally symptomatic infection in an Ebola 'hotspot': a cross-sectional
465		serosurvey. PLoS neglected tropical diseases 2016, <b>10</b> (11):e0005087.
466	30.	Becquart P, Mahlaköiv T, Nkoghe D, Leroy EM: Identification of continuous human B-cell
467		epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus. <i>PloS one</i> 2014,
468		<b>9</b> (6):e96360.
469	31.	Rudge Jr TL, Sankovich KA, Niemuth NA, Anderson MS, Badorrek CS, Skomrock ND, Cirimotich
470		CM, Sabourin CL: Development, qualification, and validation of the Filovirus Animal Nonclinical

Page 21 sur 26

471		Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay
472		for human serum samples. PloS one 2019, <b>14</b> (4):e0215457.
473	32.	Ayouba A, Touré A, Butel C, Keita AK, Binetruy F, Sow MS, Foulongne V, Delaporte E, Peeters M:
474		Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for
475		Detection of Antibodies to Zaire Ebola Virus. J Clin Microbiol 2017, 55(1):165-176.
476	33.	Larivière Y, Zola T, Stoppie E, Maketa V, Matangila J, Mitashi P, De Bie J, Muhindo-Mavoko H, Van
477		Damme P: Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of
478		a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine
479		regimen against Ebola in the Democratic Republic of the Congo: the study protocol. BMJ open
480		2021, <b>11</b> (9):e046835.
481	34.	Ayouba A, Touré A, Butel C, Keita AK, Binetruy F, Sow MS, Foulongne V, Delaporte E, Peeters M:
482		Development of a sensitive and specific serological assay based on Luminex technology for
483		detection of antibodies to Zaire Ebola virus. Journal of clinical microbiology 2017, 55(1):165-
484		176.
485	35.	Health NIo: Guidelines for good clinical laboratory practice standards. Bethesda, MD, USA:
486		National Institutes of Health 2019.
487	36.	Stevens W: Good clinical laboratory practice (GCLP): the need for a hybrid of good laboratory
488		practice and good clinical practice guidelines/standards for medical testing laboratories
489		conducting clinical trials in developing countries. Quality Assurance 2003, 10(2):83-89.
490	37.	Logue J, Tuznik K, Follmann D, Grandits G, Marchand J, Reilly C, Pettitt J, Stavale EJ, Fallah M,
491		Olinger GG: Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay
492		requires fewer study participants to power a study than the Alpha Diagnostic International
493		assay. Journal of virological methods 2018, <b>255</b> :84-90.
494	38.	Lardeux F, Torrico G, Aliaga C: Calculation of the ELISA's cut-off based on the change-point
495		analysis method for detection of Trypanosoma cruzi infection in Bolivian dogs in the absence
496		of controls. Mem Inst Oswaldo Cruz 2016, <b>111</b> (8):501-504.
497	39.	Killick R, Eckley I: changepoint: An R package for changepoint analysis. Journal of statistical
498		software 2014, <b>58</b> (3):1-19.
499	40.	Busico KM, Marshall KL, Ksiazek TG, Roels TH, Fleerackers Y, Feldmann H, Khan AS, Peters C:
500		Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic
501		<b>Republic of the Congo, 1995</b> . <i>The Journal of Infectious Diseases</i> 1999, <b>179</b> (Supplement_1):S102-
502		S107.
503	41.	Thom R, Tipton T, Strecker T, Hall Y, Akoi Bore J, Maes P, Raymond Koundouno F, Fehling SK,
504		Krähling V, Steeds K et al: Longitudinal antibody and T cell responses in Ebola virus disease
505		survivors and contacts: an observational cohort study. Lancet Infect Dis 2021, <b>21</b> (4):507-516.
506	42.	Rimoin AW, Lu K, Bramble MS, Steffen I, Doshi RH, Hoff NA, Mukadi P, Nicholson BP, Alfonso VH,
507		Olinger G: Ebola virus neutralizing antibodies detectable in survivors of the Yambuku, Zaire
508		outbreak 40 years after infection. The Journal of Infectious diseases 2018, <b>217</b> (2):223-231.
509	43.	Deshpande GR, Sapkal GN, Tilekar BN, Yadav PD, Gurav Y, Gaikwad S, Kaushal H, Deshpande KS,
510		Kaduskar O, Sarkale P: Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients.
511		The Indian Journal of medical research 2020, <b>152</b> (1-2):82.
512	44.	Marien J, Michiels J, Heyndrickx L, Nkuba-Ndaye A, Ceulemans A, Bartholomeeusen K, Madinga J,
515		ividaia-Kingedeni P, Vanierdergne V, Anuka-iviundeke S: Evaluation of a surrogate virus
514 515		neutralization test for nign-throughput serosurveillance of SARS-CoV-2. Journal of Virological
515 516	45	Wethous 2021, <b>297</b> :114228.
510	45.	Burnett LC, Lunn G, Colco R: Biosatety: guidelines for working with pathogenic and infectious
517		microorganisms. Current protocols in microbiology 2009, <b>13</b> (1):1A. 1.1-1A. 1.14.

Page 22 sur 26

- 46. Cao Z, Jin H, Wong G, Zhang Y, Jiao C, Feng N, Wu F, Xu S, Chi H, Zhao Y: The Application of a
   Safe Neutralization Assay for Ebola Virus Using Lentivirus-Based Pseudotyped Virus. Virologica
   Sinica 2021, 36(6):1648-1651.
- 52147.WHO International Standard 1st International Standard for Ebola virus (EBOV) antibodies -522Sierra Leone Convalescent Plasma Pool NIBSC code: 15/262 Instructions for use523[https://www.nibsc.org/documents/ifu/15-262.pdf]
- 52448.MacNeil A, Reed Z, Rollin PE: Serologic cross-reactivity of human IgM and IgG antibodies to five525species of Ebola virus. PLoS neglected tropical diseases 2011, 5(6):e1175.
- 52649.Kuhn J: Filoviruses: a compendium of 40 years of epidemiological, clinical, and laboratory527studies. 2008.
- 528 50. Potluri R, Kumar A, Maheshwari V, Smith C, Oriol Mathieu V, Luhn K, Callendret B, Bhandari H:
- Impact of prophylactic vaccination strategies on Ebola virus transmission: A modeling analysis.
   *Plos one* 2020, **15**(4):e0230406.

# Page 23 sur 26

Area of DRC	Year	*EBOV Seroprevalence (%)	Assay	CI	Population	Sample size (N)	Studies
Kikwit	1995	2.2	ELISA	0.3 – 4.0	Forest and City Workers	414	Busico et al. Journal of Infectious Diseases 1999, 79: S102-S107.
Watsa	2002	18.7	ELISA	14.4 – 23.5	General popualtion (pygmy)	300	Mulangu et al. <i>BMC</i> <i>infectious diseases</i> 2016, 16.1: 1-6
Sankuru	2007	11.0	ELISA	9.9 –12.7	General population	3415	Mulangu et al. <i>The</i> <i>Journal of Infectious</i> <i>Diseases</i> 2018, 217.4: 529-537
Kinshasa	2011 – 2012	2.0	Luciferase immunoprecipitation system + neutralization	0.7 – 5.1	Blood donors	752	Imke et al., Emerging Infectious Diseases. 25 (5) 2019
Boende	2015	22.5	ELISA	19.2 – 25.9	Healthcare workers	611	Doshi et al. The Journal of Infectious Diseases (2020).
Boende	2015	28.1	ELISA, Luciferase immunoprecipitation system + neutralization	24.4 – 31.4	Healthcare workers	565	Hoff et al. The Journal of infectious diseases, 2019, 219.4: 517-525
Boende	2015 – 2017	7.0	ELISA	5.0 - 8.8	General population	687	Bratcher et al. PLoS Neglected Tropical Diseases, 2021, 15.8: e0009566.
Beni, Butembo, Katwa, and Mabalako	2018- 2020	2.3	Luminex assay	1.1–4.0	Suspected cases of the tenth DRC epidemic of Ebola	600	Nkuba-Ndaye et al. <i>J Infect Di</i> s. 2022 ;226(2):352-356

# 531 **Table 1**. EBOV seroprevalence estimates using different Assays in DRC

532 \*Seroprevalence based on the GP-EBOV antigen seroreactivity

# Page 24 sur 26

# 533 **Table 2.** Participants characteristics

Characteristic	N=698	% Max	Mean (SD)	Min	
Age (year) Sex			45.0 (12.0)	19	75
Female	164	23.5			
Male	534	76.5			
Profession					
Community Health Worker	236	33.8			
Nurse	181	25.9			
First Aid Worker	177	25.4			
Hvaienist	37	5.3			
Midwife	30	4.3			
Medical Doctor	13	1.9			
Health Facility Cleaner	10	1.4			
Care Giver	7	1.0			
Other	3	0.4			
Laboratory	-				
Technician	2	0.3			
Pharmacist	•				
Assistant	2	0.3			
Place of work in					
Boende					
Health Facility					
(Hopital, Centre de Santé, Poste de Santé)	492	70.5			
Health District Office (Bureau central Zone de Santé)	8	1.1			
Croix-Rouge Boende Inspection	177	25.4			
Provinciale de la Santé	1	0.1			
Aire de Santé	10	1.4			
de la Santé	9	1.3			
Programme Elargi de Vaccination Boende	1	0.1			

535 **Table 3**: Seroprevalence for different (combinations of) antibodies against Ebola virus antigens as measured by the Luminex

	Antigen	*Cutoff	Positives	Seroprevalence	Age /year	M vs F	Direct Contact with patients: Direct vs indirect	Working Hospital vs elsewhere	Experienced Ebola outbreak/patients vs others
			n (N)	% (95% conf. Int.)	p-value	p-value	(p-value)	(p-value)	p-value
FANG ELISA	GP-EBOV-k	526 EU/ml	59 (694)	8.5 (6.5, 10.9)	0.89	0.44	0.52	0.93	0.94
	GP-EBOV-m	669 MFI/100 beads	60 (698)	8.6 (6.5,10.7)	0.03	0.93	0.05	0.63	0.09
	GP-EBOV-kis	670 MFI/100 beads	66 (698)	9.4 (7.5,11.8)	0.05	0.99	0.05	0.52	0.005
	VP40-EBOV- m	441 MFI/100 beads	87 (698)	12.4 (10.3,14.9)	0.11	0.07	0.31	0.74	0.46
Luminex	NP-EBOV-m	602 MFI/100 beads	9 (698)	1.3 (0.6,2.6)	0.41	0.40	0.13	0.26	0.07
	GP-EBOV- m+NP- EBOV-m	C1	0 (698)	0					
	GP-EBOV- m+VP40- EBOV-m	C2	10 (698)	1.4 (0.7,2.6)	0.75	0.02	0.39	0.68	0.47
	NP-EBOV- m+VP40- EBOV-m	C3	2 (698)	0.3 (0.0,1.0)					
Luminex and FANG ELISA	GP-EBOV-m + GP-EBOV-k	C4	6 (694)	0.8 (0.1,1.5)					

536 or FANG ELISA in Health care providers from Boende, DRCongo.

C1= 669MFI/100 beads for GP-EBOV-m and 602 MFI/100 beads for NP-EBOV-m

C2= 669MFI/100 beads for GP-EBOV-m and 441 MFI/100beads fo VP40-EBOV-m

C3= 602 MFI/100 beads for NP-EBOV-m and 441 MFI/100 beads for VP40-EBOV-m

0 C4= 669 MFI/100 beads for GP-EBOV-m using Luminex and 526 EU/mL for GP-EBOV-k using FANG ELISA





541

542 **Figure** 1 Pearson Correlation between FANG ELISA and Luminex

543 Seroreactivity against the glycoprotein (GP) of Ebola virus in health care providers from

544 Boende. The X axis reports the log values of the antibody titers (IgG) as measured by

545 Luminex in MFI/100 beads, while the Y axis represents antibody titers as measured by

546 FANG ELISA in EU/ml. The vertical dashed line in red represents the cutoff of the

547 changepoint analysis and the dashed horizontal line in green represents the cutoff

548 obtained from previous studies.



Figure 1 Pearson Correlation between FANG ELISA and Luminex

Seroreactivity against the glycoprotein (GP) of Ebola virus in health care providers from Boende. The X-axis reports the log values of the antibody titers (IgG) as measured by Luminex in MFI/100 beads, while the Y-axis represents antibody titers as measured by FANG ELISA in EU/ml. The vertical dashed line in red represents the cutoff of the changepoint analysis and the dashed horizontal line in green represents the cutoff obtained from previous studies.